SUPIRA MEDICAL'S STORY
Breakthrough technology for high-risk PCI and cardiogenic shock patients
Just because a surgical procedure is minimally invasive doesn’t mean it isn’t without risk. In fact, U.S. patients with advanced coronary disease undergo over 440,000 high-risk procedures each year to open up blocked arteries via catheters.
The cutting-edge percutaneous ventricular assist device (pVAD) developed by Supira Medical is designed to temporarily support the native pumping action of the heart during these necessary interventional procedures, as well as while patients recover from severe heart attacks. The company’s Supira System stands at the forefront of medical innovation, earning the coveted U.S. Food and Drug Administration Breakthrough Designation for medical devices that provide more effective treatment of potentially life-threatening or irreversible conditions or diseases.
With high-flow capabilities from a low-profile catheter pump, Supira’s technology is designed to provide full hemodynamic support and minimize vascular complications. The device offers real-time, accurate monitoring of pump performance and provides a robust platform to help physicians better treat their patients.
“Supira Medical is committed to developing a differentiated solution that provides a meaningful clinical benefit for patients requiring hemodynamic support. Early clinical experience shows tremendous promise for the Supira System, demonstrating that physicians see significant value in our approach. We are thankful for the strong partnership with Unorthodox Ventures as we look to expand our clinical program and advance the regulatory process to disrupt the standard of care for these patients.”
Dr. Nitin Salunke, President and CEO
Supira Medical in the Media
BioWorld – Supira Medical Secures $35M in Series B Funds
Cardiac Vascular News – Supira Medical’s Percutaneous Ventricular Assist Device (pVAD) to Be Highlighted During PCR Innovator’s Day and SCAI 2023
Cardiovascular News – Supira Medical to Initiate U.S. Clinical Program for pVAD System
Cath Lab Digest – SCAI: First-in-Human Trial of a Novel Percutaneous Ventricular Assist Device (pVAD) from Supira Medical
DeviceTalks – How Nitin Salunke’s Different Mindset Helped Him Shift Career from Engineer to CEO of Supira Medical
Diagnostic and Interventional Cardiology – Supira Medical Announces Successful First-in-Human Use of its Next-Generation Percutaneous Ventricular Assist Device
Diagnostic and Interventional Cardiology – Supira Medical's Next-Generation Percutaneous Ventricular Assist Device (pVAD) System to be Highlighted in a Live Case and Multiple Sessions at TCT23
Doc Wire News – A New and Effective Ventricular Assist Device for High-Risk PCI
FINSMES – Supira Medical Closes $40M In Series D Financing
FINSMES – Supira Medical Closes $30M Series C Funding
MassDevice – Newly Formed pVAD Dev Supira Medical Raises $16M
MassDevice – Supira Medical Announces First In-Human Use of pVAD
MedTech Alert – Supira Medical, a Shifamed Portfolio Company, Closes $30M in an Oversubscribed Series C Financing
NS Medical Devices – Supira Receives FDA Breakthrough Device Designation for Ventricular Assist Device
The Wall Street Journal – Shifamed Creation Supira Medical Launches with $15.5 Million Series A
Brand Recognition
European Association of Percutaneous Cardiovascular Interventions – Innovations in Heart Failure
U.S. Food and Drug Administration – Breakthrough Device Designation